Kamada Ltd. (KMDA)
KMDA Stock Price Chart
Explore Kamada Ltd. interactive price chart. Choose custom timeframes to analyze KMDA price movements and trends.
KMDA Company Profile
Discover essential business fundamentals and corporate details for Kamada Ltd. (KMDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
31 May 2013
Employees
420.00
Website
https://www.kamada.comCEO
Amir London
Description
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
KMDA Financial Timeline
Browse a chronological timeline of Kamada Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is $0.12, while revenue estimate is $50.84m.
Earnings released on 13 May 2026
EPS came in at $0.07 falling short of the estimated $0.12 by -41.67%, while revenue for the quarter reached $45.24m , missing expectations by -3.17%.
Dividend declared on 23 Mar 2026
A dividend of $0.25 per share was announced, adjusted to $0.25. The dividend was paid on 7 Apr 2026.
Earnings released on 11 Mar 2026
EPS came in at $0.06 falling short of the estimated $0.09 by -33.33%, while revenue for the quarter reached $44.68m , missing expectations by -1.63%.
Earnings released on 10 Nov 2025
EPS came in at $0.09 falling short of the estimated $0.10 by -10.00%, while revenue for the quarter reached $47.01m , missing expectations by -68.15%.
Earnings released on 13 Aug 2025
EPS came in at $0.13 surpassing the estimated $0.09 by +44.44%, while revenue for the quarter reached $44.75m , missing expectations by -71.14%.
Earnings released on 14 May 2025
EPS came in at $0.07 matching the estimated $0.07, while revenue for the quarter reached $44.02m , missing expectations by -72.75%.
Dividend declared on 17 Mar 2025
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 7 Apr 2025.
Earnings released on 5 Mar 2025
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $39.01m , missing expectations by -74.46%.
Earnings released on 13 Nov 2024
EPS came in at $0.07 matching the estimated $0.07, while revenue for the quarter reached $41.74m , missing expectations by -72.15%.
Earnings released on 14 Aug 2024
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $41.88m , beating expectations by +5.48%.
Earnings released on 8 May 2024
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $37.40m , missing expectations by -4.55%.
Earnings released on 6 Mar 2024
EPS came in at $0.09 surpassing the estimated $0.05 by +80.00%, while revenue for the quarter reached $38.35m , beating expectations by +1.70%.
Earnings released on 13 Nov 2023
EPS came in at $0.06 surpassing the estimated $0.03 by +100.00%, while revenue for the quarter reached $37.93m , beating expectations by +0.59%.
Earnings released on 16 Aug 2023
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $37.44m , missing expectations by -1.05%.
Earnings released on 24 May 2023
EPS came in at $0.04 surpassing the estimated -$0.03 by +260.00%, while revenue for the quarter reached $30.71m , missing expectations by -10.47%.
Earnings released on 15 Mar 2023
EPS came in at $0.11 surpassing the estimated $0.07 by +57.14%, while revenue for the quarter reached $45.44m , beating expectations by +1.79%.
Earnings released on 22 Nov 2022
EPS came in at $0.10 surpassing the estimated $0.04 by +133.32%, while revenue for the quarter reached $32.22m , beating expectations by +8.27%.
Earnings released on 17 Aug 2022
EPS came in at $0.07 surpassing the estimated -$0.03 by +350.00%, while revenue for the quarter reached $23.59m , missing expectations by -1.59%.
Earnings released on 17 May 2022
EPS came in at -$0.04 falling short of the estimated -$0.01 by -233.33%, while revenue for the quarter reached $28.09m , missing expectations by -13.29%.
Earnings released on 15 Mar 2022
EPS came in at -$0.10 falling short of the estimated -$0.01 by -1.00k%, while revenue for the quarter reached $31.47m , beating expectations by +41.52%.
Earnings released on 22 Nov 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -180.11%, while revenue for the quarter reached $23.03m , missing expectations by -10.13%.
Earnings released on 11 Aug 2021
EPS came in at $0.02 falling short of the estimated $0.05 by -60.00%, while revenue for the quarter reached $24.24m , missing expectations by -5.83%.
KMDA Stock Performance
Access detailed KMDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
